Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STA-5326 in Moderate Crohn's Disease
NCT00088062Phase 2Completed
- Sponsor
- Synta Pharmaceuticals Corp.
- Start
- Feb 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of apilimod in Crohn's disease (5 arms), sponsored by Synta Pharmaceuticals Corp. Primary endpoint: Safety and Tolerability. Started Feb 2004; status: completed.
02
Drugs
apilimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00088062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088062.